fluoxetine has been researched along with Endotoxin Shock in 2 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Survival of lipopolysaccharide-induced endotoxic shock was improved in Tph1(-/-) mice." | 1.39 | Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. ( Bader, M; Bode, C; Brill, A; Carbo, C; Cicko, S; Cifuni, SM; Demers, M; Duerschmied, D; Herr, N; Idzko, M; Mauler, M; Suidan, GL; Wagner, DD, 2013) |
| "In the septic shock model, all three drugs given preventively markedly decreased circulating levels of TNF-alpha and mortality (50% mortality in fluoxetine treated group, 30% in desipramine and prednisolone treated groups versus 90% in controls)." | 1.34 | Anti-inflammatory properties of desipramine and fluoxetine. ( Bichon, F; Detoc, M; Henriquet, C; Jaffuel, D; Mathieu, M; Michel, A; Portet, K; Roumestan, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duerschmied, D | 1 |
| Suidan, GL | 1 |
| Demers, M | 1 |
| Herr, N | 1 |
| Carbo, C | 1 |
| Brill, A | 1 |
| Cifuni, SM | 1 |
| Mauler, M | 1 |
| Cicko, S | 1 |
| Bader, M | 1 |
| Idzko, M | 1 |
| Bode, C | 1 |
| Wagner, DD | 1 |
| Roumestan, C | 1 |
| Michel, A | 1 |
| Bichon, F | 1 |
| Portet, K | 1 |
| Detoc, M | 1 |
| Henriquet, C | 1 |
| Jaffuel, D | 1 |
| Mathieu, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)[NCT04570449] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-11-30 | Withdrawn (stopped due to Study timeline is not feasible) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for fluoxetine and Endotoxin Shock
| Article | Year |
|---|---|
Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice.
Topics: Acute Disease; Animals; Blood Platelets; Chemotaxis; Endothelium, Vascular; Flow Cytometry; Fluoxeti | 2013 |
Anti-inflammatory properties of desipramine and fluoxetine.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Asthma; Cells, Cultured; Cytokines; Desipr | 2007 |